In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OmniSonics Medical Technologies Inc.

www.omnisonics.com

Latest From OmniSonics Medical Technologies Inc.

Deals Update (08/2007)

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.
Medical Device

The Buzz at JP Morgan--Devices: No Longer the Conference Stepchild

Over the past five years, big cap device companies have been some of the strongest performers among all life science stocks, and this year's conference represented something of a renaissance of device companies. However, most interesting wasn't so much the revival of interest in device stocks itself, but the message that device companies sent and that investors are embracing: "Forget about the hype; slow and steady wins the race."
Medical Device Strategy

Total Occlusions: Device Obstacle or Opportunity?

The market is promising for using catheters, instead of surgery, to open vascular blockages. But the right technology remains elusive.
Medical Device Clinical Trials

Fair Winds or Foul in Treating Total Occlusions?

The company that did the largest private financing last years was, surprisingly, Wilmington, MA-based OmniSonics Medical Technologies. The company is developing an innovative technology that uses acoustical energy to break up clots, plaques, and other occlusions wherever they occur in the human vasculature. OmniSonics' Series C financing will ultimately wind up raising a total of $44 million. The company's first approval, expected later this year, will come in treating peripheral disease, but the golden ring is clearly coronary arteries and that includes chronic total occlusions, a challenge that has been particularly vexing for both interventional cardiologists and medical device developers. Indeed, the recent news that CTO start-up Lumend Inc. is significantly scaling back its operations is a case in point.
Medical Device
See All

Company Information

  • Industry
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • OmniSonics Medical Technologies Inc.
  • Senior Management
  • Richard G Ganz, Pres. & CEO
    Maximillian D Fiore, SVP, R&D & Operations
    Sean McNerney, VP, Sales
  • Contact Info
  • OmniSonics Medical Technologies Inc.
    Phone: (978) 567-9980
    66 Concord St.
    Wilmington, MA 01887
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register